Last 12 months
Inside the activity.
0 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 24, 2023 Filed Oct 25, 2023 20:15 UTC |
Yu YongVP, Clinical Trial Operations
|
SaleCommon Stock | 5,200 | $19.11 | $99,351.20 |
DisclosureSEC source: 0001209191-23-053554 · doc4.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,135 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $19.106, and the range of prices were between $19.00 and $19.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 24, 2023 Filed Oct 25, 2023 20:15 UTC |
Yu YongVP, Clinical Trial Operations
|
Exercise / conversionCommon Stock | 5,200 | $6.00 | $31,200.00 |
DisclosureSEC source: 0001209191-23-053554 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2023 Filed Oct 25, 2023 20:51 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 49,987 | $19.97 | $998,365.36 |
DisclosureSEC source: 0001209191-23-053561 · doc4.xml · nonDerivative · entry 1 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,377,249 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $19.50 to $20.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| October 16, 2023 Filed Oct 16, 2023 22:39 UTC |
Thomas JohnDirector
|
SaleCommon Stock | 881 | $21.30 | $18,768.56 |
DisclosureSEC source: 0001209191-23-052904 · doc4.xml · nonDerivative · entry 2 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,460 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $21.3037, and the range of prices were between $21.17 and $21.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 16, 2023 Filed Oct 16, 2023 22:39 UTC |
Thomas JohnDirector
|
SaleCommon Stock | 2,452 | $20.50 | $50,269.43 |
DisclosureSEC source: 0001209191-23-052904 · doc4.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,341 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $20.5014, and the range of prices were between $20.10 and $20.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 20:10 UTC |
Yu YongVP, Clinical Trial Operations
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052621 · doc4.xml · derivative · entry 4 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,853 Underlying: Common Stock · 5,200 shares Expires 2029-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 20:10 UTC |
Yu YongVP, Clinical Trial Operations
|
SaleCommon Stock | 400 | $22.91 | $9,162.40 |
DisclosureSEC source: 0001209191-23-052621 · doc4.xml · nonDerivative · entry 3 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,135 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $22.906, and the range of prices were between $22.82 and $22.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 20:10 UTC |
Yu YongVP, Clinical Trial Operations
|
SaleCommon Stock | 4,800 | $21.94 | $105,299.52 |
DisclosureSEC source: 0001209191-23-052621 · doc4.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,535 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $21.9374, and the range of prices were between $21.54 and $22.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 20:10 UTC |
Yu YongVP, Clinical Trial Operations
|
Exercise / conversionCommon Stock | 5,200 | $6.00 | $31,200.00 |
DisclosureSEC source: 0001209191-23-052621 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 20:49 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 985 | $25.47 | $25,089.82 |
DisclosureSEC source: 0001209191-23-052536 · doc4.xml · nonDerivative · entry 2 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,427,236 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $25.26 to $25.5912, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 20:49 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 13,266 | $24.89 | $330,139.00 |
DisclosureSEC source: 0001209191-23-052536 · doc4.xml · nonDerivative · entry 1 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,428,221 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $24.22 to $25.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| October 03, 2023 Filed Oct 4, 2023 22:43 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 75,690 | $25.49 | $1,929,224.57 |
DisclosureSEC source: 0001209191-23-052108 · doc4.xml · nonDerivative · entry 1 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,441,487 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $25.285 to $25.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:10 UTC |
Jewett CarolineHead of Quality
|
GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $24.75 | $0.00 |
DisclosureSEC source: 0001209191-23-051909 · doc4.xml · derivative · entry 1 Jewett Caroline · CIK 0001983187 · Head of Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2033-10-01 F1 · derivative.exercise_date: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 20:34 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 2,289 | $24.12 | $55,210.68 |
DisclosureSEC source: 0001209191-23-050867 · doc4.xml · nonDerivative · entry 2 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,517,177 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $23.78 to $24.735, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 20:34 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 11,257 | $24.47 | $275,458.79 |
DisclosureSEC source: 0001209191-23-050867 · doc4.xml · nonDerivative · entry 1 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,519,466 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $24.08 to $24.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:33 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 9,600 | $24.51 | $235,296.00 |
DisclosureSEC source: 0001209191-23-050656 · doc4.xml · nonDerivative · entry 7 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,530,723 F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $24.30 to $24.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:33 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 12,740 | $24.03 | $306,142.20 |
DisclosureSEC source: 0001209191-23-050656 · doc4.xml · nonDerivative · entry 6 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,540,323 F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $23.30 to $24.29, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:33 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 7,465 | $22.47 | $167,738.55 |
DisclosureSEC source: 0001209191-23-050656 · doc4.xml · nonDerivative · entry 5 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,553,063 F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $22.09 to $22.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:10 UTC |
Yu YongVP, Clinical Trial Operations
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050643 · doc4.xml · derivative · entry 5 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,053 Underlying: Common Stock · 5,200 shares Expires 2029-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:10 UTC |
Yu YongVP, Clinical Trial Operations
|
SaleCommon Stock | 2,203 | $24.46 | $53,890.45 |
DisclosureSEC source: 0001209191-23-050643 · doc4.xml · nonDerivative · entry 4 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,135 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F4 · price: The weighted average sale price for the transaction reported was $24.4623, and the range of prices were between $24.24 and $24.755. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:10 UTC |
Yu YongVP, Clinical Trial Operations
|
SaleCommon Stock | 1,114 | $23.51 | $26,195.15 |
DisclosureSEC source: 0001209191-23-050643 · doc4.xml · nonDerivative · entry 3 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,338 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $23.5145, and the range of prices were between $23.16 and $24.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:10 UTC |
Yu YongVP, Clinical Trial Operations
|
SaleCommon Stock | 1,883 | $22.54 | $42,442.26 |
DisclosureSEC source: 0001209191-23-050643 · doc4.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,452 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $22.5397, and the range of prices were between $22.13 and $23.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:10 UTC |
Yu YongVP, Clinical Trial Operations
|
Exercise / conversionCommon Stock | 5,200 | $6.00 | $31,200.00 |
DisclosureSEC source: 0001209191-23-050643 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2023 Filed Sep 27, 2023 20:33 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 1,100 | $27.81 | $30,591.00 |
DisclosureSEC source: 0001209191-23-050656 · doc4.xml · nonDerivative · entry 4 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,560,528 F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $27.41 to $27.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 25, 2023 Filed Sep 27, 2023 20:33 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 1,900 | $26.60 | $50,540.00 |
DisclosureSEC source: 0001209191-23-050656 · doc4.xml · nonDerivative · entry 3 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,561,628 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $26.36 to $27.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 25, 2023 Filed Sep 27, 2023 20:33 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 5,511 | $25.75 | $141,908.25 |
DisclosureSEC source: 0001209191-23-050656 · doc4.xml · nonDerivative · entry 2 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,563,528 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $25.36 to $26.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 25, 2023 Filed Sep 27, 2023 20:33 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 3,947 | $24.82 | $97,964.54 |
DisclosureSEC source: 0001209191-23-050656 · doc4.xml · nonDerivative · entry 1 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,569,039 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $24.36 to $25.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 22, 2023 Filed Sep 25, 2023 22:30 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 4,621 | $27.76 | $128,269.72 |
DisclosureSEC source: 0001209191-23-050507 · doc4.xml · nonDerivative · entry 4 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,572,986 F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $27.27 to $28.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 22, 2023 Filed Sep 25, 2023 22:30 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 4,421 | $26.88 | $118,852.84 |
DisclosureSEC source: 0001209191-23-050507 · doc4.xml · nonDerivative · entry 3 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,577,607 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $26.27 to $27.26, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 22:30 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 4,678 | $28.82 | $134,815.28 |
DisclosureSEC source: 0001209191-23-050507 · doc4.xml · nonDerivative · entry 2 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,582,028 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $28.54 to $29.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 22:30 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 2,871 | $27.89 | $80,063.00 |
DisclosureSEC source: 0001209191-23-050507 · doc4.xml · nonDerivative · entry 1 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,586,706 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $27.52 to $28.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 20:35 UTC |
Yu YongVP, Clinical Trial Operations
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050282 · doc4.xml · derivative · entry 3 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,253 Underlying: Common Stock · 6,000 shares Expires 2029-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 20:35 UTC |
Yu YongVP, Clinical Trial Operations
|
SaleCommon Stock | 6,000 | $27.96 | $167,785.80 |
DisclosureSEC source: 0001209191-23-050282 · doc4.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,135 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $27.9643, and the range of prices were between $27.95 and $28.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 20:35 UTC |
Yu YongVP, Clinical Trial Operations
|
Exercise / conversionCommon Stock | 6,000 | $6.00 | $36,000.00 |
DisclosureSEC source: 0001209191-23-050282 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 20:30 UTC |
Ryder SeanGeneral Counsel
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050274 · doc4.xml · derivative · entry 3 Ryder Sean · CIK 0001937485 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 10,000 shares Expires 2031-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares shall vest on October 4, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 20:30 UTC |
Ryder SeanGeneral Counsel
|
SaleCommon Stock | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0001209191-23-050274 · doc4.xml · nonDerivative · entry 2 Ryder Sean · CIK 0001937485 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 20:30 UTC |
Ryder SeanGeneral Counsel
|
Exercise / conversionCommon Stock | 10,000 | $6.00 | $60,000.00 |
DisclosureSEC source: 0001209191-23-050274 · doc4.xml · nonDerivative · entry 1 Ryder Sean · CIK 0001937485 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 20:48 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 8,247 | $27.16 | $223,979.45 |
DisclosureSEC source: 0001209191-23-050171 · doc4.xml · nonDerivative · entry 4 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $26.67 to $27.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 20:48 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 23,920 | $26.21 | $626,962.34 |
DisclosureSEC source: 0001209191-23-050171 · doc4.xml · nonDerivative · entry 3 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,247 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $25.67 to $26.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 00:12 UTC |
Thomas JohnDirector
|
SaleCommon Stock | 3,334 | $24.99 | $83,316.66 |
DisclosureSEC source: 0001209191-23-049840 · doc4.xml · nonDerivative · entry 3 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,793 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:48 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 2,927 | $24.17 | $70,754.08 |
DisclosureSEC source: 0001209191-23-050171 · doc4.xml · nonDerivative · entry 2 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 5,000 F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $23.895 to $24.42, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:48 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 27,365 | $23.20 | $634,895.37 |
DisclosureSEC source: 0001209191-23-050171 · doc4.xml · nonDerivative · entry 1 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 7,927 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $22.88 to $23.81, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:13 UTC |
Yu YongVP, Clinical Trial Operations
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,400 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049841 · doc4.xml · derivative · entry 4 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,253 Underlying: Common Stock · 10,400 shares Expires 2029-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:13 UTC |
Yu YongVP, Clinical Trial Operations
|
SaleCommon Stock | 4,675 | $22.29 | $104,211.83 |
DisclosureSEC source: 0001209191-23-049841 · doc4.xml · nonDerivative · entry 3 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,135 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $22.2913, and the range of prices were between $22.02 and $22.77. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:13 UTC |
Yu YongVP, Clinical Trial Operations
|
SaleCommon Stock | 5,725 | $21.56 | $123,418.41 |
DisclosureSEC source: 0001209191-23-049841 · doc4.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,810 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $21.5578, and the range of prices were between $21.01 and $21.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:13 UTC |
Yu YongVP, Clinical Trial Operations
|
Exercise / conversionCommon Stock | 10,400 | $6.00 | $62,400.00 |
DisclosureSEC source: 0001209191-23-049841 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:12 UTC |
Thomas JohnDirector
|
SaleCommon Stock | 1,088 | $22.38 | $24,353.57 |
DisclosureSEC source: 0001209191-23-049840 · doc4.xml · nonDerivative · entry 2 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 479,127 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $22.3838, and the range of prices were between $22.19 and $22.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:12 UTC |
Thomas JohnDirector
|
SaleCommon Stock | 2,245 | $21.67 | $48,642.42 |
DisclosureSEC source: 0001209191-23-049840 · doc4.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,215 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $21.667, and the range of prices were between $21.17 and $22.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 14, 2023 Filed Sep 15, 2023 20:19 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 13,871 | $22.31 | $309,521.66 |
DisclosureSEC source: 0001209191-23-049587 · doc4.xml · nonDerivative · entry 4 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 35,292 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $22.005 to $22.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 14, 2023 Filed Sep 15, 2023 20:19 UTC |
Szalay Aladar10% owner
|
SaleCommon Stock | 11,405 | $21.77 | $248,284.57 |
DisclosureSEC source: 0001209191-23-049587 · doc4.xml · nonDerivative · entry 3 Szalay Aladar · CIK 0001937513 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 49,163 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $21.0044 to $22.0011, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.